HROW HARROW, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1360214 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.3%
TTM net income YoY-471.2%
TTM EPS YoY-484.6%
Revenue 3-yr CAGR38.5%
Net income 3-yr CAGR—
Margins
Gross margin73.5%
Operating margin-2.0%
Net margin-9.4%
FCF margin-6.7%
EBITDA margin-1.4%
Returns
ROE-74.8%
ROA-7.1%
ROIC (approx.)-3.5%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets93.5%
Debt / equity0.00x
Current ratio2.29x
Interest coverage-0.26x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-2.4%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $272.30M | $199.61M |
| Cost of revenue | $67.93M | $49.24M |
| Gross profit | $204.37M | $150.37M |
| R&D expense | $20.94M | $12.23M |
| SG&A expense | $152.91M | $129.06M |
| Operating income | $30.52M | $8.82M |
| Interest expense | $24.18M | $22.79M |
| Pretax income | -$1.37M | -$17.32M |
| Income tax | $3.77M | $161,000 |
| Net income | -$5.14M | -$17.48M |
| EBITDA | $32.43M | $10.67M |
| EPS (basic) | -0.14 | -0.49 |
| EPS (diluted) | -0.14 | -0.49 |
| Weighted avg. shares (diluted) | 36.76M | 35.65M |
| Balance sheet | ||
| Cash & equivalents | $72.93M | $47.25M |
| Receivables | $110.89M | $116.37M |
| Inventory | $13.52M | $10.70M |
| Current assets | $211.75M | $189.65M |
| PP&E, net | $3.26M | $3.73M |
| Goodwill | $332,000 | $332,000 |
| Intangibles | $175.17M | $184.95M |
| Total assets | $399.48M | $388.97M |
| Current liabilities | $96.30M | $91.34M |
| Long-term debt | $250.00M | $262.74M |
| Total debt | $250.00M | $262.74M |
| Total liabilities | $347.39M | $319.67M |
| Shareholders' equity | $52.45M | $69.65M |
| Net debt | $177.07M | $215.49M |
| Shares outstanding | 37.23M | 35.62M |
| Cash flow statement | ||
| Operating cash flow | $43.86M | -$22.20M |
| Capital expenditure | $887,000 | $1.59M |
| Free cash flow | $42.98M | -$23.80M |
| Investing cash flow | -$5.46M | -$33.16M |
| Financing cash flow | -$12.72M | $28.53M |
| Depreciation & amortization | $1.92M | $1.85M |
| Stock-based compensation | $12.50M | $17.62M |
Free plan shows the latest 2 periods; Pro shows all 27 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.